<DOC>
	<DOCNO>NCT00974246</DOCNO>
	<brief_summary>The purpose study assess effect treatment Advair Diskus depression use Cornell depression scale COPD patient nurse home .</brief_summary>
	<brief_title>The Effect Depressive Symptoms ECF Residents With COPD</brief_title>
	<detailed_description>We study 35 resident ECF diagnosis COPD . We evaluate depressive symptom use Cornell Depression Scale MDS 3.0 section D. We select patient currently treatment Advair start Advair Diskus50/250 1 inhalation bid period 16 week reassess Cornell Depression SCale MDS3.0 section D look change . We also go measure FEV1 FVC use spirometry treatment end 16 week . This pilot study . The number necessarily adequate achieve statistical difference-we look trend .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Adult men woman nurse home resident age 95 Stated diagnosis COPD FEV1/FVC &lt; 0.7 treated anticholinergic Presence depressive symptom measure MDS 3.0 Section D SUM Free condition likely fatal within six month Able read understand English Able willing provide inform consent guardian/LAR provide inform consent Currently pregnant Unable read understand English Free condition likely fatal within six month Enrolled hospice New treatment antidepressant within last 90 day . Current recent use ( within last 90 day ) Advair Diskus Unwilling unable provide inform consent Expected discharge within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>94 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Depression</keyword>
	<keyword>Nursing Home</keyword>
</DOC>